BIRMINGHAM, Ala., July 11, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its second quarter ended June 30, 2024, after the market closes Monday, Aug. 5, 2024. The Company will host an investor conference call at 10 a.m. ET on Tuesday, Aug. 6, 2024, to discuss its results.
The conference call may be accessed by dialing 800-579-2543 and entering the conference ID EHCQ224. International callers should dial 785-424-1699 and provide the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.
A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at https://investor.encompasshealth.com.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 163 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media contact:
Polly Manuel | 205-970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations contact:
Mark Miller | 205-970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$120.85 |
Daily Change: | -1.78 -1.45 |
Daily Volume: | 457,508 |
Market Cap: | US$12.180B |
June 18, 2025 April 24, 2025 April 24, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load